Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
Leukemia, Published online: 26 August 2023; doi:10.1038/s41375-023-02008-6Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment (Source: Leukemia)
Source: Leukemia - August 26, 2023 Category: Hematology Authors: Heinz Gisslinger Christoph Klade Pencho Georgiev Dorota Krochmalczyk Liana Gercheva-Kyuchukova Miklos Egyed Petr Dulicek Arpad Illes Halyna Pylypenko Lylia Sivcheva Ji ří Mayer Vera Yablokova Kurt Krejcy Victoria Empson Hans C. Hasselbalch Robert Kralov Source Type: research
Who wins the combat, CAR or TCR?
Leukemia, Published online: 25 August 2023; doi:10.1038/s41375-023-01976-zWho wins the combat, CAR or TCR? (Source: Leukemia)
Source: Leukemia - August 25, 2023 Category: Hematology Authors: Kun Yun Elizabeth L. Siegler Saad S. Kenderian Source Type: research
How should we interpret conclusions of TKI-stopping studies
Leukemia, Published online: 25 August 2023; doi:10.1038/s41375-023-02002-yHow should we interpret conclusions of TKI-stopping studies (Source: Leukemia)
Source: Leukemia - August 25, 2023 Category: Hematology Authors: Robert Peter Gale Junren Chen Source Type: research
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15
Leukemia, Published online: 25 August 2023; doi:10.1038/s41375-023-02011-xCorrection: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15 (Source: Leukemia)
Source: Leukemia - August 25, 2023 Category: Hematology Authors: Noriaki Tsuji Kohei Hosokawa Ryota Urushihara Mikoto Tanabe Yoshitaka Zaimoku Takamasa Katagiri Tatsuhiko Ozawa Hiroyuki Takamatsu Ken Ishiyama Hirohito Yamazaki Hiroyuki Kishi Seishi Ogawa Shinji Nakao Source Type: research
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Leukemia, Published online: 21 August 2023; doi:10.1038/s41375-023-02001-zGlasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial (Source: Leukemia)
Source: Leukemia - August 21, 2023 Category: Hematology Authors: Mikkael A. Sekeres Pau Montesinos Jan Novak Jianxiang Wang Deepa Jeyakumar Benjamin Tomlinson Jiri Mayer Erin Jou Tadeusz Robak David C. Taussig Herv é Dombret Akil Merchant Naveed Shaik Thomas O ’Brien Whijae Roh Xueli Liu Wendy Ma Christine G. DiRien Source Type: research
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
Leukemia, Published online: 19 August 2023; doi:10.1038/s41375-023-02006-8Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma (Source: Leukemia)
Source: Leukemia - August 19, 2023 Category: Hematology Authors: Anuvrat Sircar Satishkumar Singh Zijun Y. Xu-Monette Krysta Mila Coyle Laura K. Hilton Evangelia Chavdoula Parvathi Ranganathan Neeraj Jain Walter Hanel Philip Tsichlis Lapo Alinari Blake R. Peterson Jianguo Tao Natarajan Muthusamy Robert Baiocchi Narendr Source Type: research
TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia
Leukemia, Published online: 17 August 2023; doi:10.1038/s41375-023-01993-yTAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia (Source: Leukemia)
Source: Leukemia - August 17, 2023 Category: Hematology Authors: Shi Hao Tan Tze King Tan Rui Yokomori Minghui Liao Xiao Zi Huang Allen Eng Juh Yeoh Takaomi Sanda Source Type: research
S1P-S1PR3-RAS promotes the progression of S1PR3hi TAL1+ T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist
Leukemia, Published online: 17 August 2023; doi:10.1038/s41375-023-02000-0S1P-S1PR3-RAS promotes the progression of S1PR3hi TAL1+ T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist (Source: Leukemia)
Source: Leukemia - August 17, 2023 Category: Hematology Authors: Dan Zhu Tingting Jiang Deyu Ma Hongyang Zhang Jia Zhang Wenqiong Lv Maoyuan Gong Haobiao Wang Ziyang Liu Hongyu Su Lamei Zeng Shan Liu Shi Tang Bijie Yang Filippus I. Tshavuka Guo Fu Zidai Liu Danyi Peng Haiyan Liu Zijun Yan Ziyang Cao Hui Zhao Tong-Chuan Source Type: research
Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis
Leukemia, Published online: 17 August 2023; doi:10.1038/s41375-023-02007-7Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis (Source: Leukemia)
Source: Leukemia - August 17, 2023 Category: Hematology Authors: Natalia J. Gurule Kenneth C. Malcolm Chelsea Harris Jennifer R. Knapp Brian P. O ’Connor Jazalle McClendon William J. Janssen Frank Fang Yao Lee Caitlin Price Jackson Osaghae-Nosa Emily A. Wheeler Christine M. McMahon Eric M. Pietras Daniel A. Pollyea S Source Type: research
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Leukemia, Published online: 17 August 2023; doi:10.1038/s41375-023-01999-6Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients (Source: Leukemia)
Source: Leukemia - August 17, 2023 Category: Hematology Authors: Ekaterina Jahn Maral Saadati Pierre Fenaux Marco Gobbi Gail J. Roboz Lars Bullinger Pavlo Lutsik Anna Riedel Christoph Plass Nikolaus Jahn Claudia Walter Karlheinz Holzmann Yong Hao Sue Naim Nicholas Schreck Julia Krzykalla Axel Benner Harold N. Keer Moha Source Type: research
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia
Leukemia, Published online: 16 August 2023; doi:10.1038/s41375-023-02005-9Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia (Source: Leukemia)
Source: Leukemia - August 16, 2023 Category: Hematology Authors: Theresa Eifert Chen-Jen Hsu Alicia L. Becker Sarah Graessle Arik Horne Franziska Bemmann Qirui Zhang Michael Heuser Valeri Vasioukhin Sebastian Scholl Andreas Hochhaus Florian Siegerist Nicole Endlich Lars Bullinger Steven W. Lane Simon Haas Tina M. Schno Source Type: research
Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications
Leukemia, Published online: 14 August 2023; doi:10.1038/s41375-023-01996-9Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications (Source: Leukemia)
Source: Leukemia - August 14, 2023 Category: Hematology Authors: Jin Jung Daehun Kwag Yonggoo Kim Jong-Mi Lee Ari Ahn Hoon Seok Kim Byunggyu Bae Silvia Park Hee-Je Kim Byung-Sik Cho Myungshin Kim Source Type: research
CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma
Leukemia, Published online: 12 August 2023; doi:10.1038/s41375-023-01997-8CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma (Source: Leukemia)
Source: Leukemia - August 12, 2023 Category: Hematology Authors: Neetha Parameswaran Liping Luo Lingjun Zhang Joel Chen Frank P. DiFilippo Charlie Androjna David A. Fox Sarah L. Ondrejka Eric D. Hsi Deepa Jagadeesh Daniel J. Lindner Feng Lin Source Type: research
Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
Leukemia, Published online: 12 August 2023; doi:10.1038/s41375-023-02004-wRisk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC (Source: Leukemia)
Source: Leukemia - August 12, 2023 Category: Hematology Authors: Sandra Huber Constance Baer Stephan Hutter Frank Dicker Irene Fuhrmann Manja Meggendorfer Christian Pohlkamp Wolfgang Kern Torsten Haferlach Claudia Haferlach Gregor Hoermann Source Type: research
Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation
Leukemia, Published online: 11 August 2023; doi:10.1038/s41375-023-01998-7Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation (Source: Leukemia)
Source: Leukemia - August 11, 2023 Category: Hematology Authors: Jakob Nordberg N ørgaard Niels Abildgaard Anna Lys én Galina Tsykunova Annette Juul Vangsted Cristina Jo ão Nora Remen Lene Kongsgaard Nielsen Liv Osnes Caroline Stokke James P. Connelly Mona-Elisabeth R. Revheim Fredrik Schjesvold Source Type: research
